The authors synthesize current evidence on how a very‑low‑carbohydrate, high‑fat ketogenic diet and probiotic supplementation might interact with the gut microbiota–host metabolic axis in polyendocrine metabolic ovarian syndrome (PMOS). They conclude that the combined approach is biologically plausible but remains untested in randomized trials.
Study and findings
Yang and colleagues present a narrative review that integrates mechanistic data on the ketogenic diet (KD), probiotic supplementation, and gut microbiota dysbiosis in PMOS, formerly known as PCOS. The review outlines three strands of evidence: (1) KD reduces carbohydrate intake, induces hepatic ketogenesis, promotes weight loss, improves insulin sensitivity, and attenuates systemic inflammation; (2) KD may also diminish beneficial taxa such as Bifidobacterium, potentially compromising microbial homeostasis; (3) Probiotics can restore SCFA‑producing bacteria, reinforce intestinal barrier function, modulate bile‑acid metabolism, and lower circulating lipopolysaccharide, thereby mitigating inflammation and insulin resistance. The authors cite several clinical studies in which KD alone lowered body weight, HOMA‑IR, and testosterone in small PCOS cohorts, and a meta‑analysis of 17 probiotic trials showing modest improvements in fasting glucose, HOMA‑IR, triglycerides, and cholesterol. No randomized controlled trial has examined KD together with probiotics in women with PMOS, so the review’s central proposition—that the two interventions may act synergistically via the gut‑microbiota–host axis—remains hypothetical.
Clinical interpretation
For clinicians managing PMOS, the review highlights two practical considerations. First, KD can be an effective metabolic intervention, especially for patients with obesity and insulin resistance, but its impact on gut microbial composition warrants attention. Second, probiotic supplementation offers a strategy to counteract potential KD‑induced loss of beneficial microbes and to enhance short‑chain fatty acid production, which may further improve insulin signaling and inflammatory status. However, because the combined regimen has not been evaluated in a controlled setting, clinicians should view it as an experimental adjunct rather than a standard of care. The existing evidence supports the plausibility of a complementary effect, but the magnitude of any additional benefit over KD alone is unknown.
Limitations and open questions
The principal limitation is the absence of direct clinical data on the KD‑probiotic combination in PMOS; all conclusions are derived from separate KD or probiotic studies and from animal models of microbiota transfer. Consequently, the review cannot establish causality, quantify effect size, or identify patient subgroups most likely to benefit. Additional uncertainties include the optimal probiotic strains, dosage, and duration, as well as the specific macronutrient ratios and caloric targets required to achieve ketosis without excessive loss of beneficial bacteria. Future research should prioritize randomized crossover or parallel‑group trials that compare KD alone, probiotics alone, and the combined regimen, with standardized microbiome sequencing and metabolic endpoints.
Source
Yang Y, Dai F, He X, Zhao P, Chen Q. Ketogenic diet combined with probiotics for polyendocrine metabolic ovarian syndrome: research progress from the perspective of the gut microbiota-host metabolic axis. Front Nutr. 2026;13:1945464. doi: 10.3389/fnut.2026.1945464. PMID: 42751354.